Satralizumab
Enspryng (satralizumab) is an antibody pharmaceutical. Satralizumab was first approved as Enspryng on 2020-08-14. It is used to treat neuromyelitis optica in the USA. It has been approved in Europe to treat neuromyelitis optica.
Trade Name | Enspryng |
---|---|
Common Name | Satralizumab |
Indication | neuromyelitis optica |
Drug Class | Monoclonal antibodies: humanized, immunomodulating |
